Carter Gould
Stock Analyst at Cantor Fitzgerald
(3.94)
# 586
Out of 5,147 analysts
218
Total ratings
57.36%
Success rate
8.4%
Average return
Main Sectors:
Stocks Rated by Carter Gould
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GILD Gilead Sciences | Maintains: Overweight | $135 → $155 | $148.95 | +4.06% | 17 | Feb 11, 2026 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $985 → $1,205 | $1,051.99 | +14.54% | 15 | Feb 5, 2026 | |
| PFE Pfizer | Reiterates: Neutral | $27 | $27.65 | -2.35% | 17 | Feb 4, 2026 | |
| MRK Merck & Co. | Maintains: Neutral | $116 → $120 | $123.82 | -3.09% | 12 | Feb 4, 2026 | |
| AMGN Amgen | Maintains: Neutral | $315 → $350 | $388.16 | -9.83% | 19 | Feb 4, 2026 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $740 → $800 | $781.67 | +2.34% | 22 | Feb 2, 2026 | |
| NUVL Nuvalent | Maintains: Overweight | $100 → $112 | $101.95 | +9.86% | 2 | Oct 31, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $245 → $250 | $232.08 | +7.72% | 18 | Oct 9, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $535 → $485 | $496.83 | -2.38% | 4 | Aug 5, 2025 | |
| BMY Bristol-Myers Squibb Company | Reiterates: Neutral | $55 | $62.37 | -11.82% | 16 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $61.74 | - | 1 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $160 → $165 | $132.25 | +24.76% | 12 | Dec 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $29.79 | -32.86% | 6 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $190 → $180 | $191.82 | -6.16% | 24 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $60 | $15.44 | +288.60% | 4 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3 | $0.58 | +413.61% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $1.68 | +435.71% | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $95 | $62.22 | +52.68% | 2 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $25 → $20 | $4.19 | +377.33% | 5 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $62 → $73 | $113.79 | -35.85% | 4 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $12 | $2.43 | +393.83% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2 → $1.5 | $0.42 | +253.02% | 6 | Mar 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $392 → $380 | $125.83 | +201.99% | 1 | Jan 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $75 → $82 | $101.27 | -19.03% | 5 | Jan 16, 2019 |
Gilead Sciences
Feb 11, 2026
Maintains: Overweight
Price Target: $135 → $155
Current: $148.95
Upside: +4.06%
Eli Lilly and Company
Feb 5, 2026
Maintains: Overweight
Price Target: $985 → $1,205
Current: $1,051.99
Upside: +14.54%
Pfizer
Feb 4, 2026
Reiterates: Neutral
Price Target: $27
Current: $27.65
Upside: -2.35%
Merck & Co.
Feb 4, 2026
Maintains: Neutral
Price Target: $116 → $120
Current: $123.82
Upside: -3.09%
Amgen
Feb 4, 2026
Maintains: Neutral
Price Target: $315 → $350
Current: $388.16
Upside: -9.83%
Regeneron Pharmaceuticals
Feb 2, 2026
Maintains: Overweight
Price Target: $740 → $800
Current: $781.67
Upside: +2.34%
Nuvalent
Oct 31, 2025
Maintains: Overweight
Price Target: $100 → $112
Current: $101.95
Upside: +9.86%
AbbVie
Oct 9, 2025
Maintains: Overweight
Price Target: $245 → $250
Current: $232.08
Upside: +7.72%
Vertex Pharmaceuticals
Aug 5, 2025
Maintains: Overweight
Price Target: $535 → $485
Current: $496.83
Upside: -2.38%
Bristol-Myers Squibb Company
Apr 23, 2025
Reiterates: Neutral
Price Target: $55
Current: $62.37
Upside: -11.82%
Apr 22, 2025
Initiates: Overweight
Price Target: n/a
Current: $61.74
Upside: -
Dec 23, 2024
Maintains: Overweight
Price Target: $160 → $165
Current: $132.25
Upside: +24.76%
Nov 1, 2024
Maintains: Overweight
Price Target: $18 → $20
Current: $29.79
Upside: -32.86%
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $190 → $180
Current: $191.82
Upside: -6.16%
Aug 14, 2024
Maintains: Overweight
Price Target: $200 → $60
Current: $15.44
Upside: +288.60%
Jun 13, 2024
Maintains: Overweight
Price Target: $7 → $3
Current: $0.58
Upside: +413.61%
Jun 11, 2024
Initiates: Overweight
Price Target: $9
Current: $1.68
Upside: +435.71%
May 23, 2024
Maintains: Overweight
Price Target: $100 → $95
Current: $62.22
Upside: +52.68%
Apr 16, 2024
Maintains: Overweight
Price Target: $25 → $20
Current: $4.19
Upside: +377.33%
Feb 29, 2024
Maintains: Overweight
Price Target: $62 → $73
Current: $113.79
Upside: -35.85%
May 5, 2023
Maintains: Overweight
Price Target: $14 → $12
Current: $2.43
Upside: +393.83%
Mar 21, 2023
Maintains: Equal-Weight
Price Target: $2 → $1.5
Current: $0.42
Upside: +253.02%
Jan 20, 2022
Maintains: Equal-Weight
Price Target: $392 → $380
Current: $125.83
Upside: +201.99%
Jan 16, 2019
Downgrades: Neutral
Price Target: $75 → $82
Current: $101.27
Upside: -19.03%